Sutro Biopharma Inc STRO.OQ STRO.O is expected to show a rise in quarterly revenue when it reports results for the period ending September 30 2025
The South San Francisco California-based company is expected to report a 44.5% increase in revenue to $12.31 million from $8.52 million a year ago, according to the mean estimate from 10 analysts, based on LSEG data.
LSEG's mean analyst estimate for Sutro Biopharma Inc is for a loss of 38 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 4 "hold" and 1 "sell" or "strong sell."
The mean earnings estimate of analysts had risen by about 16.9% in the last three months.
Wall Street's median 12-month price target for Sutro Biopharma Inc is $2.00, about 59.9% above its last closing price of $0.80
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | -0.41 | -0.40 | -0.14 | Beat | 65.2 |
Mar. 31 2025 | -0.70 | -0.71 | -0.91 | Missed | -28.6 |
Dec. 31 2024 | -0.78 | -0.83 | -0.89 | Missed | -7.1 |
Sep. 30 2024 | -0.73 | -0.73 | -0.59 | Beat | 19.7 |
Jun. 30 2024 | -0.76 | -0.79 | -0.59 | Beat | 25.5 |
Mar. 31 2024 | -0.88 | -0.92 | -0.95 | Missed | -3 |
Dec. 31 2023 | -0.82 | 0.52 | Beat | 163.2 | |
Sep. 30 2023 | -0.74 | -0.74 | -0.81 | Missed | -10.1 |
This summary was machine generated August 9 at 00:39 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。